Neoadjuvant Long-course Chemoradiotherapy Followed by PD-1 Monoclonal Antibody for Locally Advanced Mid-low Rectal Cancer
Latest Information Update: 24 Jul 2024
At a glance
- Drugs Sintilimab (Primary)
- Indications Adenocarcinoma; Rectal cancer
- Focus Therapeutic Use
- Acronyms NLCCRIT-LARC
Most Recent Events
- 17 Jul 2024 New trial record
- 11 Jul 2024 Status changed from active, no longer recruiting to recruiting.